Editorial Notes

[Editorial Notes] Drug discrepancies and State lethargy

The recent Glycol poisoning event in India has thrown light upon the faulty drugs administration and management in India regarding their manufacturing, regulation and sale. This reflects the State lethargy and pegs an urgent need for a strong drug regulatory framework in India.
By IASToppers
March 04, 2020

Drug discrepancies and State lethargy

For IASToppers’ Editorial Simplified Archive, click here


An incident has been reported recently in Udhampur district of Jammu where 12 children have died due to poisoned cough syrup (Coldbest-PC) and many are fighting for their lives in a hospital.

Reason of Death:

  • A team of doctors at the Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, attributed the deaths to the presence of diethylene glycol in the cough syrup which was consumed by all the dead children.
  • Diethylene glycol is an anti-freezing agent that causes acute renal failure in the human body followed by paralysis, breathing difficulties and ultimately death.

Glycol poisoning events in India:

  • This is the fourth mass glycol poisoning event in India that has been caused due to a pharmaceutical drug.
  • In 1973, there was a similar incident at the Children’s Hospital, Egmore in Chennai that caused the deaths of 14 children.
  • In 1986, similar poisoning at Mumbai’s J.J. Hospital caused the deaths of 14 patients who were otherwise on the path to recovery.
  • In 1998, 33 children died in two hospitals located in New Delhi due to similar poisoning.
  • In all three cases, the manufacturer of the suspect cough syrup, due to negligence or human error, failed to detect and contain the level of diethylene glycol in the syrup, thereby causing poisoning of the patients who consumed it.

Tracking the sold bottles:

  • The immediate concern for doctors, pharmacists and the drug regulators should be to prevent any more deaths.
  • The only way to do so is to account for each and every bottle of the poisoned syrup that has ever been sold in the Indian market and stop patients from consuming this drug any further.
  • Any patient who has consumed even a spoon of the syrup should then immediately be referred to a hospital for treatment.
  • According to the information available on the website of the United States Food and Drug Administration (USFDA), in 1937, when the United States faced a similar situation with glycol poisoning, its entire field force of 239 inspectors and chemists were assigned to the task of tracking down every single bottle of the drug.
  • Even if a patient claimed to have thrown out the bottle, the investigators scoured the street until they found the discarded bottle. This effort was accompanied by a publicity blitz over radio and television.

Indian scenario:

  • Such public health measures are not seen in India as authorities are simply not communicating the seriousness of the issue to the general public.
  • At most, the authorities in Himachal Pradesh (H.P.), who are responsible for oversight of the manufacturer of this syrup, have made general statements that they have ordered the withdrawal of the drug from all the other States where it was marketed.
  • However, there is no transparency in the recall process and information about recalls and batch numbers is not being communicated through authoritative channels.
  • There is no public announcement by the Drug Controller General of India (DCGI), which is responsible for overall regulation of the entire Indian market.
  • The suspect product, although manufactured in H.P., has been sold across the country.
  • The website of the DCGI, which is supposed to communicate drug alerts and product recalls, has no mention of Coldbest-PC as being dangerous as of this writing.

Need for a recall policy:

  • India has not notified any binding guidelines or rules on recalling dangerous drugs from the market.
  • The 59th report of the Parliamentary Standing Committee on Health as well as the World Health Organization (in its national regulatory assessment) had warned the DCGI on the lack of a national recall framework in India.
  • A set of recall guidelines was drafted in 2012 but never notified into law.
  • In 2016, a report submitted to the Ministry of Health suggested measures to reform the drug regulatory framework but the government is yet to file its response.
  • While a national recall of this adulterated medicine is the immediate need, the administration also needs to quickly identify which other pharmaceutical companies have received the spurious ingredient that was supplied to the manufacturer in H.P. from a trader in Chennai
  •  It is very likely that the trader in question marketed the same ingredient to other pharmaceutical companies, who, like the manufacturer at the centre of the present scandal, may have failed to test it for its identity and purity.
  • It is important for regulatory enforcement to raid and seize the records of the trader in Chennai and verify its sales.

Way Forward:

  • Need for binding guidelines or rules on recalling dangerous drugs from the market.
  • Public awareness campaign to communicate the seriousness of the issue.
  • Making the list of banned or prohibited drugs.
  • Strict criteria for Quality and quantity of Drugs.
  • Fixing accountability of the drug manufacturer.
  • Stringent punishment for any deviation.
  • Transparency in the procedures undertaken.


  • There is an urgent need to shun the larger lethargy and arrogance of the bureaucracy and take quick actions to keep public safe from unethical practices of pharmaceutical companies. A strong drug regulatory framework is required to check the lackadaisical response of drug regulators, fixing their accountability and legal action in case of discrepancy.
[Ref: The Hindu]
Mains 2020 Editorial Notes

IT on Facebook

Facebook Pagelike Widget


Calendar Archive

October 2020
« Sep